28Sep
28Sep
After dry spell, Boston has a new unicorn
Boston finally has a new unicorn after a nearly three-month dry spell for companies crossing the $1 billion valuation mark. Wasabi Technologies Inc. has become Boston's latest unicorn after raising $125 million in a Series D round led by L2 Point Management. The Boston-based company also announced the expansion of its debt facility with MGG Investment Group by $125 million. Wasabi said the $250 million in new funding puts its valuation over $1.1 billion. Read more >>
27Sep
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
Corbus Pharmaceuticals Holdings, Inc., an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors. Read more >>
27Sep
Cloud storage startup Wasabi raises $250M to reach unicorn status
The cloud services sector is still dominated by Amazon and the other so-called “hyperscalers” — e.g. the Microsoft Azures, Google Cloud Platforms and IBM Clouds of the world. According to Synergy Group, an IT market research firm, Amazon, Microsoft and Google together held a 65% share of the global cloud services market as of Q2, up 61% year-over-year. Read more >>
21Sep
RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology
RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is injectable, the material may be delivered in a minimally invasive procedure. Read more >>
21Sep
Music & Cloud Storage Pioneer: 10 Burning Questions with David Friend
David Friend may singlehandedly be the most interesting person I’ve ever met. From his storied background in the music industry to being a wildly successful CEO with six successful startups under his belt, there is always something new and different to learn from him and about him. During one of our recent meetings, I told him many people have a similar opinion about him, and he just giggled. He said he never thought of himself that way and was just interested...
21Sep
eSight™ Assistive Device for Visually Impaired Available for Demonstrations at AAO
Leading vision enhancement platform, eSight, is holding demonstrations of its current medical device model, eSight 4, at the American Academy of Ophthalmology Conference in Chicago, Illinois, Sept. 30 through Oct. 3, 2022. eSight representatives will be onsite to discuss the company’s expansion into the telehealth space and scalable access for the low-vision individuals who need it most. eSight 4 is a clinically validated, FDA-registered low vision device designed to help patients with central vision loss achieve up to 20/20 visual...
17Sep
Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED
Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a one-year $263,000 Small Business Innovation Research (SBIR) grant to: (i) optimize a formulation of sildenafil (generic name of Viagra) loaded into Zylö’s proprietary silica-based Z-pods and (ii) demonstrate that the topical formulation is comparable in efficacy to orally administered sildenafil in a mouse model of erectile dysfunction [ED], with aged mice. The grant is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases,...
16Sep
RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial
RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite®, the company’s bone adhesive biomaterial. RevBio has optimized its bone adhesive biomaterial primarily by adjusting the pH of the material as it undergoes its self-setting reaction. In addition, the company has also increased the...
15Sep